Published in Int J Cancer on May 15, 2009
Relationship between male pattern baldness and the risk of aggressive prostate cancer: an analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. J Clin Oncol (2014) 2.12
Obesity and prostate cancer: weighing the evidence. Eur Urol (2012) 2.01
Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer (2012) 1.87
Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev (2009) 1.76
Obesity and cancer risk: recent review and evidence. Curr Oncol Rep (2011) 1.76
Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT. Cancer Res (2011) 1.71
Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavor. Cancer Res (2011) 1.38
A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Hum Mol Genet (2010) 1.18
Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer. Cancer Epidemiol Biomarkers Prev (2010) 1.17
Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer. Cancer Res (2010) 1.06
Milk and dairy consumption among men with prostate cancer and risk of metastases and prostate cancer death. Cancer Epidemiol Biomarkers Prev (2012) 1.05
Calcium intake increases risk of prostate cancer among Singapore Chinese. Cancer Res (2010) 1.04
Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines. Mol Cancer Ther (2009) 1.04
Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels. Carcinogenesis (2011) 1.04
Low circulating IGF-I bioactivity is associated with human longevity: findings in centenarians' offspring. Aging (Albany NY) (2012) 1.01
Insulin-like growth factor pathway genetic polymorphisms, circulating IGF1 and IGFBP3, and prostate cancer survival. J Natl Cancer Inst (2014) 0.98
Dietary glycemic index, glycemic load, insulin index, fiber and whole-grain intake in relation to risk of prostate cancer. Cancer Causes Control (2010) 0.98
Plasma insulin-like growth factor 1 is positively associated with low-grade prostate cancer in the Health Professionals Follow-up Study 1993-2004. Int J Cancer (2011) 0.95
Coffee consumption and risk of prostate cancer: an up-to-date meta-analysis. Eur J Clin Nutr (2013) 0.93
Caveolin-1-LRP6 signaling module stimulates aerobic glycolysis in prostate cancer. Cancer Res (2013) 0.91
Association between circulating levels of IGF-1 and IGFBP-3 and lung cancer risk: a meta-analysis. PLoS One (2012) 0.91
Metabolic imbalance and prostate cancer progression. Int J Mol Epidemiol Genet (2010) 0.89
The association between cancer and amyotrophic lateral sclerosis. Cancer Causes Control (2012) 0.89
Pooled cohort study on height and risk of cancer and cancer death. Cancer Causes Control (2013) 0.88
Insulin-like growth factors and risk of kidney cancer in men. Br J Cancer (2010) 0.88
Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer. Int J Cancer (2014) 0.87
Plasma levels of acid-labile subunit, free insulin-like growth factor-I, and prostate cancer risk: a prospective study. Cancer Epidemiol Biomarkers Prev (2010) 0.86
Association of body mass index and prostate cancer mortality. Obes Res Clin Pract (2013) 0.84
Effect of low-intensity aerobic exercise on insulin-like growth factor-I and insulin-like growth factor-binding proteins in healthy men. Int J Endocrinol (2010) 0.84
Insulin-like growth factor pathway genes and blood concentrations, dietary protein and risk of prostate cancer in the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). Int J Cancer (2013) 0.84
Does milk intake promote prostate cancer initiation or progression via effects on insulin-like growth factors (IGFs)? A systematic review and meta-analysis. Cancer Causes Control (2017) 0.84
Influence of Intramuscular Application of Autologous Conditioned Plasma on Systemic Circulating IGF-1. J Sports Sci Med (2011) 0.83
The role of dietary fat throughout the prostate cancer trajectory. Nutrients (2014) 0.83
Psychosocial biomarker research: integrating social, emotional and economic factors into population studies of aging and health. Soc Cogn Affect Neurosci (2010) 0.81
The effects of resistance exercise on physical performance and health-related quality of life in prostate cancer patients: a systematic review. Support Care Cancer (2015) 0.81
Emerging options in growth hormone therapy: an update. Drug Des Devel Ther (2011) 0.80
Racial differences in the association of insulin-like growth factor pathway and colorectal adenoma risk. Cancer Causes Control (2013) 0.80
Associations of insulin and insulin-like growth factors with physical performance in old age in the Boyd Orr and Caerphilly studies. PLoS One (2012) 0.80
Body size across the life course and prostate cancer in the Health Professionals Follow-up Study. Int J Cancer (2015) 0.80
Prediagnostic Body Mass Index Trajectories in Relation to Prostate Cancer Incidence and Mortality in the PLCO Cancer Screening Trial. J Natl Cancer Inst (2016) 0.79
Inhibition of the insulin-like growth factor-1 receptor enhances effects of simvastatin on prostate cancer cells in co-culture with bone. Cancer Microenviron (2013) 0.79
Insulin-like growth factors and liver cancer risk in male smokers. Br J Cancer (2010) 0.79
A study of caloric restriction versus standard diet in overweight men with newly diagnosed prostate cancer: a randomized controlled trial. Prostate (2013) 0.79
Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort. BMC Med (2016) 0.79
Metabolic risk factors in prostate cancer. Cancer (2010) 0.78
To die or to survive, a fatal question for the destiny of prostate cancer cells after androgen deprivation therapy. Cancers (Basel) (2011) 0.78
Epithelial cancers in the post-genomic era: should we reconsider our lifestyle? Cancer Metastasis Rev (2013) 0.78
ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents. Oncotarget (2015) 0.78
Association between endogenous sex steroid hormones and insulin-like growth factor proteins in US men. Cancer Causes Control (2014) 0.77
Control of IGFBP-2 Expression by Steroids and Peptide Hormones in Vertebrates. Front Endocrinol (Lausanne) (2014) 0.77
The Somatotropic Axis in Human Aging: Framework for the Current State of Knowledge and Future Research. Cell Metab (2016) 0.77
Dose-sparing and safety-enhancing effects of an IGF-I-based dosing regimen in short children treated with growth hormone in a 2-year randomized controlled trial: therapeutic and pharmacoeconomic considerations. Clin Endocrinol (Oxf) (2014) 0.77
Global Igfbp1 deletion does not affect prostate cancer development in a c-Myc transgenic mouse model. J Endocrinol (2011) 0.77
Apigenin Modulates Insulin-like Growth Factor Axis: Implications for Prevention and Therapy of Prostate Cancer. Curr Drug Targets (2012) 0.75
Waist-hip Ratio (WHR), a Better Predictor for Prostate Cancer than Body Mass Index (BMI): Results from a Chinese Hospital-based Biopsy Cohort. Sci Rep (2017) 0.75
Expression of insulin-like growth factor family genes in clear cell renal cell carcinoma. Contemp Oncol (Pozn) (2016) 0.75
Serum Insulin-Like Growth Factor Axis and the Risk of Pancreatic Cancer: Systematic Review and Meta-Analysis. Nutrients (2017) 0.75
Growth and development: how safe is growth hormone therapy for children? Nat Rev Endocrinol (2010) 0.75
Insulin-like growth factor (IGF)-I, IGF binding protein-3, and prostate cancer: correlation with Gleason score. Int Braz J Urol (2015) 0.75
Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels. Int J Cancer (2016) 0.75
Is birthweight associated with total and aggressive/lethal prostate cancer risks? A systematic review and meta-analysis. Br J Cancer (2016) 0.75
Low-level arsenic exposure from drinking water is associated with prostate cancer in Iowa. Environ Res (2017) 0.75
Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences. Oncotarget (2017) 0.75
Milk disrupts p53 and DNMT1, the guardians of the genome: implications for acne vulgaris and prostate cancer. Nutr Metab (Lond) (2017) 0.75
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
Measuring inconsistency in meta-analyses. BMJ (2003) 128.20
Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 122.24
Operating characteristics of a rank correlation test for publication bias. Biometrics (1994) 47.97
Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ (2001) 20.65
Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol (1992) 8.82
Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet (2004) 8.77
Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science (1998) 6.50
Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation (2002) 5.45
When can a risk factor be used as a worthwhile screening test? BMJ (1999) 3.56
Nutritional regulation of the insulin-like growth factors. Endocr Rev (1994) 3.18
Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst (1998) 3.10
Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst (2000) 2.34
Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med (2008) 2.33
Serum insulin-like growth factor-1 is not a useful marker of prostate cancer. BJU Int (1999) 2.14
Methods for summarizing the risk associations of quantitative variables in epidemiologic studies in a consistent form. Am J Epidemiol (1996) 1.70
Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer (1997) 1.69
Insulin-like growth factor-I, IGF binding protein-3, and breast cancer in young women: a comparison of risk estimates using different peptide assays. Cancer Epidemiol Biomarkers Prev (2005) 1.67
Geographic distribution of prostate cancer incidence in the era of PSA testing, Connecticut, 1984 to 1998. Urology (2004) 1.60
Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab (1995) 1.51
Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab (1993) 1.50
Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab (2000) 1.49
In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res (2001) 1.46
High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J Clin Oncol (2004) 1.41
Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer (2005) 1.38
The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models. Cytokine Growth Factor Rev (2005) 1.37
Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes Control (2005) 1.33
Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res (2003) 1.31
IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African-Americans. Carcinogenesis (2007) 1.28
Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev (2007) 1.27
Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev (1999) 1.27
Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab (1993) 1.26
Insulin-Like Growth Factor (IGF) family and prostate cancer. Crit Rev Oncol Hematol (2006) 1.25
Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol (2002) 1.21
The role of insulin-like growth factor binding proteins. Neuroendocrinology (2006) 1.19
Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endocrinol (Oxf) (1997) 1.19
IGF-1 and IGFBP-3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Int J Cancer (2007) 1.19
Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2006) 1.15
Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies. Br J Cancer (2006) 1.14
Insulin-like growth factors and prostate cancer. Epidemiol Rev (2001) 1.10
Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). Cancer Causes Control (2003) 1.07
Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev (2001) 1.06
Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival. Eur Urol (2005) 1.03
Null association between insulin-like growth factors, insulin-like growth factor-binding proteins, and prostate cancer in a prospective study. Cancer Epidemiol Biomarkers Prev (2001) 1.03
Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy. J Urol (2005) 1.03
Insulin-like growth factor 1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection. Urology (1999) 1.00
Insulin-like growth factor-binding protein-1 and prostate cancer. J Natl Cancer Inst (1999) 0.99
Insulin-like growth factor-I and prostate cancer: a meta-analysis. Br J Cancer (2001) 0.99
Serum levels of insulin-like growth factor-I and insulin-like growth factor-I binding protein-3: quality control for studies of stored serum. Cancer Epidemiol Biomarkers Prev (2007) 0.97
Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. J Clin Endocrinol Metab (2000) 0.93
Pitfalls of immunoassay and sample for IGF-I: comparison of different assay methodologies using various fresh and stored serum samples. Clin Biochem (2005) 0.93
A prospective study of the insulin-like growth factor axis in relation with prostate cancer in the SU.VI.MAX trial. Cancer Epidemiol Biomarkers Prev (2005) 0.92
Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer. J Clin Endocrinol Metab (2001) 0.91
Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval. J Clin Endocrinol Metab (2004) 0.90
Screen-detected prostate cancer and the insulin-like growth factor axis: results of a population-based case-control study. Int J Cancer (2004) 0.90
The significance of serum levels of insulin-like growth factor-1 in patients with prostate cancer. BJU Int (2000) 0.87
Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls. Eur Urol (2005) 0.85
Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2005) 0.85
Are plasma insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) useful markers of prostate cancer? Int J Biol Markers (2004) 0.83
Insulin-like growth factor-1 and insulin-like growth factor binding protein-3 for prostate cancer detection in patients undergoing prostate biopsy. J Urol (2002) 0.83
IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging. Eur Urol (2005) 0.83
Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence. Urology (2001) 0.83
Low serum insulin-like growth factor 1 (IGF-1): a significant association with prostate cancer. Tech Urol (2000) 0.83
Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia. Urol Int (2004) 0.82
Analysis of relations between serum levels of epitestosterone, estradiol, testosterone, IGF-1 and prostatic specific antigen in men with benign prostatic hyperplasia and carcinoma of the prostate. Physiol Res (2000) 0.81
Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml. J Surg Oncol (2007) 0.80
Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer. Prostate (2003) 0.79
Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening. Urology (2004) 0.78
The significance of PSA/IGF-1 ratio in differentiating benign prostate hyperplasia from prostate cancer. Dis Markers (2000) 0.78
[Vascular endothelial growth factor and insulin-like-growth factors in prostate cancer. ]. Urologiia (2004) 0.78
[Quantitative analysis of IGF-1 and its application in the diagnosis of prostate cancer]. Hua Xi Yi Ke Da Xue Xue Bao (2002) 0.78
Putative role of serum insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels in the development of prostate cancer in Arab men. Prostate Cancer Prostatic Dis (2005) 0.77
Prostatic fluid-free insulin-like growth factor-1 in relation to prostate cancer. BJU Int (2001) 0.77
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (2008) 11.08
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet (2009) 8.39
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
UK health performance: findings of the Global Burden of Disease Study 2010. Lancet (2013) 6.11
Effect of infant feeding on the risk of obesity across the life course: a quantitative review of published evidence. Pediatrics (2005) 5.47
Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol (2008) 4.72
Patterns of hospital transfer for self-poisoned patients in rural Sri Lanka: implications for estimating the incidence of self-poisoning in the developing world. Bull World Health Organ (2006) 4.47
Increase in state suicide rates in the USA during economic recession. Lancet (2012) 4.28
Using natural experiments to evaluate population health interventions: new Medical Research Council guidance. J Epidemiol Community Health (2012) 4.26
Suicide by intentional ingestion of pesticides: a continuing tragedy in developing countries. Int J Epidemiol (2003) 4.01
Effects of prolonged and exclusive breastfeeding on child height, weight, adiposity, and blood pressure at age 6.5 y: evidence from a large randomized trial. Am J Clin Nutr (2007) 3.96
Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet (2009) 3.76
NHS waiting lists and evidence of national or local failure: analysis of health service data. BMJ (2003) 3.60
Lessons from the withdrawal of rofecoxib. BMJ (2004) 3.33
Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ (2005) 3.09
Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. Lancet Oncol (2014) 2.96
Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study. BMJ (2013) 2.86
Association of body mass index with suicide mortality: a prospective cohort study of more than one million men. Am J Epidemiol (2005) 2.82
Comparison of the associations of body mass index and measures of central adiposity and fat mass with coronary heart disease, diabetes, and all-cause mortality: a study using data from 4 UK cohorts. Am J Clin Nutr (2010) 2.82
Impact of 2008 global economic crisis on suicide: time trend study in 54 countries. BMJ (2013) 2.80
Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control (2008) 2.68
No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial. Br J Nutr (2007) 2.57
Resuscitation at birth and cognition at 8 years of age: a cohort study. Lancet (2009) 2.57
General practice based intervention to prevent repeat episodes of deliberate self harm: cluster randomised controlled trial. BMJ (2002) 2.57
Hypertensive disorders in pregnancy and subsequently measured cardiovascular risk factors. Obstet Gynecol (2009) 2.56
Insomnia and the risk of acute myocardial infarction: a population study. Circulation (2011) 2.54
Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol (2009) 2.51
Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol (2007) 2.45
The effect of breastfeeding on mean body mass index throughout life: a quantitative review of published and unpublished observational evidence. Am J Clin Nutr (2005) 2.43
Effects of technology or maternal factors on perinatal outcome after assisted fertilisation: a population-based cohort study. Lancet (2008) 2.38
Opportunity cost of antidepressant prescribing in England: analysis of routine data. BMJ (2005) 2.35
Help-seeking behaviour in men and women with common mental health problems: cross-sectional study. Br J Psychiatry (2005) 2.32
Does breastfeeding influence risk of type 2 diabetes in later life? A quantitative analysis of published evidence. Am J Clin Nutr (2006) 2.32
Variants in ADCY5 and near CCNL1 are associated with fetal growth and birth weight. Nat Genet (2010) 2.30
Paternal age and schizophrenia: a population based cohort study. BMJ (2004) 2.27
Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care (2009) 2.23
Issues in the reporting and conduct of instrumental variable studies: a systematic review. Epidemiology (2013) 2.19
How much loss to follow-up is acceptable in long-term randomised trials and prospective studies? Arch Dis Child (2008) 2.18
Was the economic crisis 1997-1998 responsible for rising suicide rates in East/Southeast Asia? A time-trend analysis for Japan, Hong Kong, South Korea, Taiwan, Singapore and Thailand. Soc Sci Med (2009) 2.18
Psychotic experiences and psychotic disorders at age 18 in relation to psychotic experiences at age 12 in a longitudinal population-based cohort study. Am J Psychiatry (2013) 2.17
Suicide and the internet. BMJ (2008) 2.13
Fetal growth and childhood behavioral problems: results from the ALSPAC cohort. Am J Epidemiol (2006) 2.09
Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials. Am J Clin Nutr (2006) 2.04
Suicide and occupation: the impact of socio-economic, demographic and psychiatric differences. Psychol Med (2007) 2.03
Meta-analyses of observational and genetic association studies of folate intakes or levels and breast cancer risk. J Natl Cancer Inst (2006) 2.01
Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer (2007) 2.00
Blood pressure in early adolescence in the offspring of preeclamptic and normotensive pregnancies. J Hypertens (2009) 1.97
Height, wealth, and health: an overview with new data from three longitudinal studies. Econ Hum Biol (2009) 1.95
COX-2 selective nonsteroidal anti-inflammatory drugs and risk of gastrointestinal tract complications and myocardial infarction: an instrumental variable analysis. Epidemiology (2013) 1.94
Temporal changes in resting heart rate and deaths from ischemic heart disease. JAMA (2011) 1.94
Factors influencing help seeking in mentally distressed young adults: a cross-sectional survey. Br J Gen Pract (2004) 1.90
Tobacco smoking and thyroid function: a population-based study. Arch Intern Med (2007) 1.89
Thyrotropin levels and risk of fatal coronary heart disease: the HUNT study. Arch Intern Med (2008) 1.88
The Early Transmission Dynamics of H1N1pdm Influenza in the United Kingdom. PLoS Curr (2009) 1.87
Origin of the two-dimensional electron gas carrier density at the LaAlO3 on SrTiO3 interface. Phys Rev Lett (2008) 1.86
Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis (2009) 1.86
Exposures in childhood, adolescence and early adulthood and breast cancer risk: a systematic review of the literature. Breast Cancer Res Treat (2003) 1.85
Suicide in England and Wales 1861-2007: a time-trends analysis. Int J Epidemiol (2010) 1.84
Patterns of hospital admission for adult psychiatric illness in England: analysis of Hospital Episode Statistics data. Br J Psychiatry (2004) 1.83
Improvement in survival after paraquat ingestion following introduction of a new formulation in Sri Lanka. PLoS Med (2008) 1.83
Variations in the hospital management of self harm in adults in England: observational study. BMJ (2004) 1.83
Prospective study of peer victimization in childhood and psychotic symptoms in a nonclinical population at age 12 years. Arch Gen Psychiatry (2009) 1.81
Epidemiology of intentional self-poisoning in rural Sri Lanka. Br J Psychiatry (2005) 1.81
Association of adult body mass index and height with anxiety, depression, and suicide in the general population: the HUNT study. Am J Epidemiol (2007) 1.74
Suicide rates in young men in England and Wales in the 21st century: time trend study. BMJ (2008) 1.74
Relationship between antidepressant sales and secular trends in suicide rates in the Nordic countries. Br J Psychiatry (2006) 1.74
Cohort profile: The Boyd Orr cohort--an historical cohort study based on the 65 year follow-up of the Carnegie Survey of Diet and Health (1937-39). Int J Epidemiol (2005) 1.73
Does breast-feeding in infancy lower blood pressure in childhood? The Avon Longitudinal Study of Parents and Children (ALSPAC). Circulation (2004) 1.72
Changing trends in the prevalence of common mental disorders in Taiwan: a 20-year repeated cross-sectional survey. Lancet (2012) 1.72
Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT. Cancer Res (2011) 1.71
Recurrence of pre-eclampsia across generations: exploring fetal and maternal genetic components in a population based cohort. BMJ (2005) 1.70
School intervention to improve mental health of students in Santiago, Chile: a randomized clinical trial. JAMA Pediatr (2013) 1.70
Segmental and global longitudinal strain and strain rate based on echocardiography of 1266 healthy individuals: the HUNT study in Norway. Eur J Echocardiogr (2009) 1.69
Choice of poison for intentional self-poisoning in rural Sri Lanka. Clin Toxicol (Phila) (2006) 1.68
Birthweight and mortality in adulthood: a systematic review and meta-analysis. Int J Epidemiol (2011) 1.67
Young adults' perceptions of GPs as a help source for mental distress: a qualitative study. Br J Gen Pract (2006) 1.65
Glycaemic control in newly diagnosed diabetes patients and mortality from ischaemic heart disease: 20-year follow-up of the HUNT Study in Norway. Eur Heart J (2009) 1.64
IQ and non-clinical psychotic symptoms in 12-year-olds: results from the ALSPAC birth cohort. Br J Psychiatry (2008) 1.64
Hypertension in pregnancy and later cardiovascular risk: common antecedents? Circulation (2010) 1.62
The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT Study. Eur J Endocrinol (2007) 1.62
Oxycodone for cancer-related pain: meta-analysis of randomized controlled trials. Arch Intern Med (2006) 1.62
IQ in early adulthood and mortality by middle age: cohort study of 1 million Swedish men. Epidemiology (2009) 1.62
Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study. BMJ (2009) 1.59
Associations of prepregnancy cardiovascular risk factors with the offspring's birth weight. Am J Epidemiol (2007) 1.59
Advanced paternal age: how old is too old? J Epidemiol Community Health (2006) 1.55
Whole grain and refined grain consumption and the risk of type 2 diabetes: a systematic review and dose-response meta-analysis of cohort studies. Eur J Epidemiol (2013) 1.55